 |
Benzoate and phenylacetate |
|---|---|
| Trade Name | Ucephan |
| Orphan Indication | For adjunctive therapy in the prevention and treatment of hyperammonemia in patients with urea cycle enzymopathy due to carbamylphosphate synthetase, ornithine, transcarbamylase, or argininosuccinate synthetase deficiency |
| USA Market Approval | USA |
| USA Designation Date | 1986-01-21 00:00:00 |
| Sponsor | ImmunexImmunex;2525 McGaw Avenue, P.O. Box 19791;Irvine, California, 92623 |
